8-K Announcements
6Material company update
May 15, 2026·SEC
Material company update
Apr 23, 2026·SEC
Material company update
Apr 3, 2026·SEC
Indaptus Therapeutics, Inc.(INDP)Earnings, Financials & Key Ratios
INDP•NASDAQ
$3.41
Price updated Jun 27, 2026
AboutIndaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B virus and human immunodeficiency virus infection, which is in Phase I clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. was incorporated in 2021 and is headquartered in New York, New York.Show more
- Revenue$0
- EBITDA-$20M-29.1%
- Net Income-$21M-38.8%
- EPS (Diluted)-21.58-1240.4%
- ROE-587.59%-213.3%
INDP Price & Volume
Indaptus Therapeutics, Inc. (INDP) stock price & volume — 10-year historical chart
Loading chart...
Clinical Development Costs Threaten Immediate Liquidity Runway
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent liquidity and dilution
"Indaptus Therapeutics faces a precarious outlook as its clinical-stage bacterial platform development continues to drive significant quarterly operating losses, reaching $8.2 million in 2025Q4. The company lacks commercial revenue to offset these expenditures, forcing a reliance on dilutive financing and stock-based compensation, which totaled $227.2K in 2026Q1. Investors should monitor the rapid depletion of the cash position, which fell from $13.4 million in 2023Q4 to just $1.5 million in 2026Q1, as this trajectory suggests an imminent need for capital to maintain operational continuity."
Verdict Logic
the company's liquidity buffer has been severely compromised, with cash and equivalents plummeting to $1.5 million in 2026Q1, which warrants extreme caution regarding potential near-term dilution.
INDP Growth Metrics
Indaptus Therapeutics, Inc. (INDP) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-19.75%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-270.76%
Return on Capital
10 Years-128.9%
5 Years-186.29%
3 Years-279.66%
Last Year-558.97%
INDP Recent Earnings
Indaptus Therapeutics, Inc. (INDP) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 12/12 qtrs (100%)
Q2 2026Latest
May 15, 2026Metric
Actual
Est
EPS
$0.23+87.7%
$1.87
Rev
—
—
Q2 2026
Mar 17, 2026Metric
Actual
Est
EPS
$3.10+28.9%
$4.36
Rev
—
—
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$2.98+28.5%
$4.17
Rev
—
—
Q3 2025
Aug 13, 2025Metric
Actual
Est
EPS
$9.09+1.6%
$9.24
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 15, 2026 | $0.23vs $1.87+87.7% | — |
| Q2 2026 | Mar 17, 2026 | $3.10vs $4.36+28.9% | — |
| Q4 2025 | Nov 12, 2025 | $2.98vs $4.17+28.5% | — |
| Q3 2025 | Aug 13, 2025 | $9.09vs $9.24+1.6% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Indaptus Therapeutics, Inc. (INDP)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $3.41 | $5.97M | -0.16 | — | — | -587.59% | — | |
| $38.85 | $7.98B | -14.03 | — | — | -68.16% | — | |
| $108.12 | $8.83B | -29.30 | -16.72% | -612.17% | -25.02% | — | |
| $31.00 | $3.12B | -9.42 | -4.26% | -156.36% | -68.97% | — | |
| $55.83 | $8.55B | 20.16 | 87.32% | 65.95% | 87.36% | — | |
| $2.83 | $202.47M | -2.01 | — | — | -30.9% | — |
Compare INDP vs Peers
Indaptus Therapeutics, Inc. (INDP) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
INDP SEC Filings & Documents
Indaptus Therapeutics, Inc. (INDP) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when INDP posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
INDP Frequently Asked Questions
Indaptus Therapeutics, Inc. (INDP) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is INDP profitable?
Indaptus Therapeutics, Inc. (INDP) reported a net loss of $18.9M for fiscal year 2025.
Dividend & Returns
What is INDP's return on equity?
Indaptus Therapeutics, Inc. (INDP) has a return on equity (ROE) of -587.6%. Negative ROE indicates the company is unprofitable.
What is Indaptus Therapeutics, Inc.'s free cash flow?
Indaptus Therapeutics, Inc. (INDP) had negative free cash flow of $17.3M in fiscal year 2025, likely due to heavy capital investments.